Thus, PTPN2‐deficient CAR T cells might be especially effective against tumours such as oestrogen receptor‐negative and triple‐negative breast cancers (Shields et al, 2013) or lung cancers (Feng et al, 2017) that have low PTPN2 levels. The gene discussed is PTPN2; the disease is neoplasm.